NDC product
Irinotecan hydrochloride
NDC 16714-131 · Northstar Rx LLC
Key facts
| Product NDC | 16714-131 |
|---|---|
| Proprietary name | Irinotecan hydrochloride |
| Nonproprietary name | Irinotecan hydrochloride |
| Substances | IRINOTECAN HYDROCHLORIDE |
| Dosage form | INJECTION |
| Route | INTRAVENOUS |
| Labeler | Northstar Rx LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA212993 |
| Pharmacologic classes | Topoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA] |
| Marketing start | Nov 15, 2020 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: